MPC-2130

MPC-2130 is a broad-acting, apoptosis-inducing small molecule with potential antineoplastic activity. Its exact mechanism of action has not been fully elucidated, but it exhibits proapoptotic activities in tumor cells, including membrane phosphatidylserine externalization, release of cytochrome C from mitochondria, caspase activation, cell condensation, and DNA fragmentation[1][9]. It also acts as an inhibitor of matrix metalloproteinases (MMPs), contributing to its anticancer effects[2]. Preclinical studies demonstrated significant cancer cell killing activity in ovarian cancer, prostate cancer, Burkitt’s lymphoma, and T-cell lymphoma[7]. The drug was developed for the treatment of advanced metastatic tumors or blood cancers as well as refractory cancers that progressed despite previous chemotherapy[6][7].